Inositol News and Research

RSS
Elan enrolls first patient dosing in phase 2a study of ELND005 in Down syndrome

Elan enrolls first patient dosing in phase 2a study of ELND005 in Down syndrome

Transition Therapeutics' ELND005 receives Fast Track Designation from FDA

Transition Therapeutics' ELND005 receives Fast Track Designation from FDA

Study offers new insights into how genome gets regulated by signalling molecules within human cells

Study offers new insights into how genome gets regulated by signalling molecules within human cells

Location of altered brain metabolite levels found in bipolar I patients

Location of altered brain metabolite levels found in bipolar I patients

Article analyzes role of nutrition in mood swings

Article analyzes role of nutrition in mood swings

High-fiber diets may control progression of prostate cancer

High-fiber diets may control progression of prostate cancer

Disabling ItpkB enzyme improves function of Natural Killer cells

Disabling ItpkB enzyme improves function of Natural Killer cells

Enrollment begins in Elan’s ELND005 Phase 2 trial for agitation/aggression associated with AD

Enrollment begins in Elan’s ELND005 Phase 2 trial for agitation/aggression associated with AD

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

Elan second quarter total revenue increases 6% to $288.0 million

Elan second quarter total revenue increases 6% to $288.0 million

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Everett Labs announces availability of Pregnitude for women with fertility problems

Everett Labs announces availability of Pregnitude for women with fertility problems

Research identifies several new means to potentially target cancer

Research identifies several new means to potentially target cancer

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Transition, Elan to modify collaboration agreement for development, commercialization of ELND005

Transition, Elan to modify collaboration agreement for development, commercialization of ELND005

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

New analysis evaluates association between hemolysis, mortality in patients with PNH

New analysis evaluates association between hemolysis, mortality in patients with PNH

Breast cancer breakthrough

Breast cancer breakthrough

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease

Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease